Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL28195801 | 0.98 | MAOA (0.39) | MAOAMAOB | |
| SCHEMBL12820490 | 0.81 | MAOA (0.40) | MAOAMAOB | |
| SCHEMBL30302988 | 0.77 | MAOA (0.41) | MAOAMAOB | |
| SCHEMBL345581 | 0.77 | EGLN1 (0.33) | — | |
| SCHEMBL993140 | 0.75 | MAOA (0.42) | MAOAMAOB | |
| Hydrochloric Acid SCHEMBL16057049 | 0.75 | EGLN1 (0.32) | — | |
| SCHEMBL19844616 | 0.75 | KDM4E (0.31) | — | |
| SCHEMBL2882844 | 0.75 | — | — | |
| SCHEMBL3259179 | 0.74 | — | — | |
| SCHEMBL24989267 | 0.73 | LMNA (0.37) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4805909-B2 | — | — | 2011-11-02 | — | — | JP | claimed |
| EP-3275861-A1 | TETRACYCLINE COMPOUNDS | Tetraphase Pharmaceuticals, Inc. (US) | 2018-01-31 | — | — | EP | disclosed |
| US-20170334841-A1 | TETRACYCLINE COMPOUNDS | TETRAPHASE PHARMACEUTICALS, INC. | 2017-11-23 | — | — | US | disclosed |
| EP-2470500-B1 | TETRACYCLINE COMPOUNDS | TETRAPHASE PHARMACEUTICALS INC (US) | 2017-10-04 | — | — | EP | disclosed |
| US-9624166-B2 | Tetracycline compounds | TETRAPHASE PHARMACEUTICALS, INC. (US) | 2017-04-18 | — | — | US | disclosed |
| US-20120208788-A1 | Tetracycline Compounds | TETRAPHASE PHARMACEUTICALS, INC. | 2012-08-16 | — | — | US | disclosed |
| US-6861418-B2 | 4-aryl substituted indolinones | SUGEN, INC. (US) | 2005-03-01 | — | — | US | disclosed |
| US-20040157909-A1 | 4-Aryl substituted indolinones | SUGEN, INC. | 2004-08-12 | — | — | US | disclosed |
| US-6677368-B2 | 4-aryl substituted indolinones | SUGEN, INC. | 2004-01-13 | — | — | US | disclosed |
| US-6599902-B2 | For treating or preventing a protein kinase related disorder | SUGEN, INC. | 2003-07-29 | — | — | US | disclosed |
| US-20030125370-A1 | 5-ARALKYSUFONYL-3-(PYRROL-2-YLMETHYLIDENE)-2-INDOLINONE DERIVATIVES AS KINASE INHIBITORS | SUGEN, INC. | 2003-07-03 | — | — | US | disclosed |
| US-20030069297-A1 | 4-aryl substituted indolinones | SUGEN, INC. | 2003-04-10 | — | — | US | disclosed |
| WO-2002096361-A2 | 5-ARALKYLSULFONYL-3- (PYRROL-2-YLMETHYLIDENE)-2-INDOLINONE DERIVATIVES AS KINASE INHIBITORS | SUGEN, INC. (US) | 2002-12-05 | — | — | WO | disclosed |
| US-5672615-A | MATRIX-DEGRADING METALLOPROTEINASE INHIBITORS | NOVARTIS CORPORATION (US) | 1997-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030069297-A1 | 4-aryl substituted indolinones | CDK5, CAMK4, TNK2 | MAOA 1144/4885MAOB 1182/4885 |
| US-20040157909-A1 | 4-Aryl substituted indolinones | CDK5, CAMK4, TNK2 | MAOA 1144/4885MAOB 1182/4885 |
| US-20170334841-A1 | TETRACYCLINE COMPOUNDS | TUBB, TUBA1A, TUBA1C | MAOA 1967/4885MAOB 1699/4885 |
| US-20030125370-A1 | 5-ARALKYSUFONYL-3-(PYRROL-2-YLMETHYLIDENE)-2-INDOLINONE DERIVATIVES AS KINASE INHIBITORS | DMPK, ADK, MAP3K20 | MAOA 2289/4885MAOB 2166/4885 |
| US-20120208788-A1 | Tetracycline Compounds | TUBA1A, TUBA1C, TUBB1 | MAOA 2165/4885MAOB 2000/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.